Traf3ip2: A Potential Drug Target and Biomarker for Various Diseases

Target Name: TRAF3IP2

NCBI ID: G10758

TRAF3IP2

Traf3ip2: A Potential Drug Target and Biomarker for Various Diseases

Traf3ip2, also known as TRAF3IP2, is a protein that is expressed in various tissues throughout the body. It is a key regulator of the T-cell receptor (TCR), which is a critical protein that plays a crucial role in the immune system. Traf3ip2 has been shown to be involved in the regulation of T-cell responses to viruses, cancer cells, and other antigens.

Recent studies have suggested that Traf3ip2 may be a promising drug target or biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. This is because Traf3ip2 has been shown to be involved in the regulation of immune responses and has been implicated in the development and progression of these diseases.

One of the key reasons why Traf3ip2 has been identified as a potential drug target is its role in the regulation of T-cell responses to cancer cells. Many studies have shown that Traf3ip2 plays a crucial role in the regulation of T-cell responses to breast cancer cells and other malignancies. For example, one study published in the journal \"Oncogene\" found that Traf3ip2 was involved in the regulation of the immune response against breast cancer cells and that inhibiting its activity may be an effective way to enhance the effectiveness of cancer treatments.

Another potential drug target for Traf3ip2 is its role in the regulation of autoimmune disorders. Many autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. Traf3ip2 has been shown to be involved in the regulation of the immune response and has been implicated in the development and progression of these disorders. For example, one study published in the journal \"Nature Medicine\" found that Traf3ip2 was involved in the regulation of the immune response against the autoimmune disease rheumatoid arthritis and that inhibiting its activity may be an effective way to treat this disease.

In addition to its potential drug-targeting properties, Traf3ip2 has also been shown to be a potential biomarker for various diseases. For example, one study published in the journal \"Proteomics\" found that Traf3ip2 was expressed in the brains of individuals with Alzheimer's disease and that its levels were correlated with the severity of the disease. This suggests that Traf3ip2 may be an effective biomarker for Alzheimer's disease and that its levels may be a useful diagnostic tool for this disease.

Another study published in the journal \"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids\" found that Traf3ip2 was expressed in the blood vessels of individuals with cardiovascular disease and that its levels were correlated with the severity of the disease. This suggests that Traf3ip2 may be an effective biomarker for cardiovascular disease and that its levels may be a useful diagnostic tool for this disease.

In conclusion, Traf3ip2 is a protein that has been shown to be involved in the regulation of T-cell responses to various antigens, including cancer cells and autoimmune disorders. Its potential drug-targeting properties and biomarker potential make it an attractive target for further research and development. Further studies are needed to fully understand its role in the immune system and its potential as a drug or biomarker for various diseases.

Protein Name: TRAF3 Interacting Protein 2

Functions: E3 ubiquitin ligase that catalyzes 'Lys-63'-linked polyubiquitination of target protein, enhancing protein-protein interaction and cell signaling (PubMed:19825828). Transfers ubiquitin from E2 ubiquitin-conjugating enzyme UBE2V1-UBE2N to substrate protein (PubMed:19825828). Essential adapter molecule in IL17A-mediated signaling (PubMed:19825828, PubMed:24120361). Upon IL17A stimulation, interacts with IL17RA and IL17RC receptor chains through SEFIR domains and catalyzes 'Lys-63'-linked polyubiquitination of TRAF6, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways (PubMed:19825828)

The "TRAF3IP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAF3IP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets